JP2008540557A - フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法 - Google Patents

フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法 Download PDF

Info

Publication number
JP2008540557A
JP2008540557A JP2008511333A JP2008511333A JP2008540557A JP 2008540557 A JP2008540557 A JP 2008540557A JP 2008511333 A JP2008511333 A JP 2008511333A JP 2008511333 A JP2008511333 A JP 2008511333A JP 2008540557 A JP2008540557 A JP 2008540557A
Authority
JP
Japan
Prior art keywords
group
ether group
formula
ether
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008511333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540557A5 (https=
Inventor
ティモシー シー． バーデン
ピーター リー
エデュアルド ジェー． マルティネス
ウェイン シー． シェイラー
ジョン ジェー． タレー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbia Inc
Original Assignee
Microbia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbia Inc filed Critical Microbia Inc
Publication of JP2008540557A publication Critical patent/JP2008540557A/ja
Publication of JP2008540557A5 publication Critical patent/JP2008540557A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2008511333A 2005-05-11 2006-05-11 フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法 Pending JP2008540557A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67978505P 2005-05-11 2005-05-11
PCT/US2006/018153 WO2006122216A2 (en) 2005-05-11 2006-05-11 Processes for production of phenolic 4-biphenylylazetidin-2-ones

Publications (2)

Publication Number Publication Date
JP2008540557A true JP2008540557A (ja) 2008-11-20
JP2008540557A5 JP2008540557A5 (https=) 2009-08-13

Family

ID=37397290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511333A Pending JP2008540557A (ja) 2005-05-11 2006-05-11 フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法

Country Status (15)

Country Link
US (1) US20080200669A1 (https=)
EP (1) EP1885703A4 (https=)
JP (1) JP2008540557A (https=)
KR (1) KR20080017345A (https=)
CN (1) CN101218213A (https=)
AU (1) AU2006244043A1 (https=)
BR (1) BRPI0608970A2 (https=)
CA (1) CA2608075A1 (https=)
EA (1) EA200702464A1 (https=)
IL (1) IL187287A0 (https=)
MA (1) MA29539B1 (https=)
MX (1) MX2007014172A (https=)
NO (1) NO20076371L (https=)
WO (1) WO2006122216A2 (https=)
ZA (1) ZA200710721B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545700A (ja) * 2005-05-25 2008-12-18 マイクロビア インコーポレーテッド ４−（ビフェニリル）アゼチジン−２−オンホスホン酸類の製造方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AU2004288822A1 (en) * 2003-11-10 2005-05-26 Microbia, Inc. 4-Biarylyl-1-phenylazetidin-2-ones
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
JP2008543744A (ja) * 2005-05-09 2008-12-04 マイクロビア インコーポレーテッド 有機金属ベンゼンホスホナートカップリング剤
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010113184A1 (en) * 2009-04-02 2010-10-07 Lupin Limited Kinetic resolution of (4s)-4-phenyl-3-[5(rs)-(4-fluorophenyl)-5-hydroxypentanoyl] -1,3 oxazolidin 2-one to (5s) isomer via lipase catalyzed enantioselective esterification of the (5r) isomer
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102285932B (zh) * 2011-09-01 2013-06-12 浙江大学 一种依替米贝中间体的制备方法
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508637A (ja) * 1991-07-23 1994-09-29 シェリング・コーポレーション 血清コレステロール低下薬として有用な置換β−ラクタム化合物およびそれらの製法
WO2002066464A1 (fr) * 2001-02-23 2002-08-29 Kotobuki Pharmaceutical Co., Ltd. Composes de beta-lactame, leur procede de production et agents d'abaissement du taux de cholesterol contenant ces composes
JP2004516280A (ja) * 2000-12-21 2004-06-03 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な１，２−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
JP2005053931A (ja) * 1998-12-07 2005-03-03 Schering Plough Corp アゼチジノンの合成プロセス
JP2008542205A (ja) * 2005-05-06 2008-11-27 マイクロビア インコーポレーテッド ４−ビフェニリルアゼチジン−２−オンの製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
EE05453B1 (et) * 2001-03-28 2011-08-15 Schering Corporation Protsess asetidinoonvahehendite valmistamiseks
WO2004099132A2 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Process for the preparation of trans-isomers of diphenylazetidinone derivatives
AU2004288822A1 (en) * 2003-11-10 2005-05-26 Microbia, Inc. 4-Biarylyl-1-phenylazetidin-2-ones
WO2006116499A1 (en) * 2005-04-26 2006-11-02 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
US20090131395A1 (en) * 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508637A (ja) * 1991-07-23 1994-09-29 シェリング・コーポレーション 血清コレステロール低下薬として有用な置換β−ラクタム化合物およびそれらの製法
JP2005053931A (ja) * 1998-12-07 2005-03-03 Schering Plough Corp アゼチジノンの合成プロセス
JP2004516280A (ja) * 2000-12-21 2004-06-03 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な１，２−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
WO2002066464A1 (fr) * 2001-02-23 2002-08-29 Kotobuki Pharmaceutical Co., Ltd. Composes de beta-lactame, leur procede de production et agents d'abaissement du taux de cholesterol contenant ces composes
JP2008542205A (ja) * 2005-05-06 2008-11-27 マイクロビア インコーポレーテッド ４−ビフェニリルアゼチジン−２−オンの製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012021813; ＣＬＡＤＥＲ，Ｊ．Ｗ．　ｅｔ　ａｌ: '２-Ａｚｅｔｉｄｉｎｏｎｅ　Ｃｈｏｌｅｓｔｅｒｏｌ　Ａｂｓｏｒｐｔｉｏｎ　Ｉｎｈｉｂｉｔｏｒｓ：　Ｓｔｒｕｃｔｕｒｅ-Ａｃｔｉｖｉｔｙ　Ｒｅｌａｔｉｏｎｓｈｉｐｓ　ｏｎ　ｔｈｅ　Ｈｅｔｅｒｏｃｙｃｌｉ' Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３９，　Ｎｏ．１９, 1996, ｐ．３６８４-３６９３ *
JPN6012021814; '２-ａｚｅｔｉｄｉｎｏｎｅ　ｃｈｏｌｅｓｔｅｒｏｌ　ａｂｓｏｒｐｔｉｏｎ　ｉｎｈｉｂｉｔｏｒｓ：　ｉｎｃｒｅａｓｅｄ　ｐｏｔｅｎｃｙ　ｂｙ　ｓｕｂｓｔｉｔｕｔｉｏｎ　ｏｆ　ｔｈｅ　Ｃ-４　ｐｈｅｎｙｌ' Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．６，　Ｎｏ．９, 1998, ｐ．１４２９-１４３７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545700A (ja) * 2005-05-25 2008-12-18 マイクロビア インコーポレーテッド ４−（ビフェニリル）アゼチジン−２−オンホスホン酸類の製造方法

Also Published As

Publication number Publication date
EP1885703A4 (en) 2009-09-02
KR20080017345A (ko) 2008-02-26
EA200702464A1 (ru) 2008-04-28
MA29539B1 (fr) 2008-06-02
EP1885703A2 (en) 2008-02-13
AU2006244043A1 (en) 2006-11-16
US20080200669A1 (en) 2008-08-21
WO2006122216A2 (en) 2006-11-16
ZA200710721B (en) 2008-10-29
MX2007014172A (es) 2008-04-02
WO2006122216A3 (en) 2007-09-13
CA2608075A1 (en) 2006-11-16
IL187287A0 (en) 2008-08-07
CN101218213A (zh) 2008-07-09
BRPI0608970A2 (pt) 2010-02-17
NO20076371L (no) 2008-02-11

Similar Documents

Publication Publication Date Title
JP2008540557A (ja) フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法
JP2008545700A (ja) ４−（ビフェニリル）アゼチジン−２−オンホスホン酸類の製造方法
CA2438961C (en) Beta-lactam compounds, manufacturing methods of the compounds and serum hypocholesterolemic agents containing the compounds
US20090227786A1 (en) Processes for preparing intermediate compounds useful for the preparation of ezetimibe
KR101156588B1 (ko) 에제티밉의 제조방법 및 이에 사용되는 중간체
WO2008106900A1 (en) Method of manufacturing (3r, 4s) -1- (4-fluorophenyl) -3- [ (3s) -3- (4 -fluorophenyl) -3-hydroxypropyl) ] -4- (4-hyd roxyphenyl) -2-azetidinone
US6350878B1 (en) Intermediates for the synthesis of epothilones and methods for their preparation
JP2007538041A (ja) ジフェニルアゼチジノン誘導体の製造方法
JP2008542205A (ja) ４−ビフェニリルアゼチジン−２−オンの製造方法
US7550608B2 (en) Processes for the preparation of docetaxel
RU2434860C1 (ru) Способ получения (6r)-3-гексил-4-гидрокси-6-ундецил-5,6-дигидропиран-2-она и промежуточного соединения, применяемого в данном способе
CN101213170A (zh) 制备4-联苯基氮杂环丁烷-2-酮化合物的方法
EP4006018B1 (en) Method for synthesizing 2-((6-(hydroxymethyl)chromene-5-yl)oxy)-1-phenylethanone derivative
US5973161A (en) Enantioselective synthesis of cyclopentenes
JP4162891B2 (ja) テトラヒドロチオフェン誘導体の製造方法
JPH04368365A (ja) アゼチジノン誘導体の製法
JPWO1999043641A1 (ja) ２位に置換基を有するビタミンｄ誘導体のａ環部分の合成中間体化合物
JP2009132650A (ja) イソオキサゾリジン化合物
JPS643188B2 (https=)
JPH09241266A (ja) ビス−テトラヒドロフラン誘導体の製造方法
JP2000256236A (ja) 光学活性アルコール化合物の製造方法
JPH0321025B2 (https=)
JP2006328058A (ja) ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121030